|Bid||240.15 x 900|
|Ask||275.00 x 1100|
|Day's Range||260.70 - 270.25|
|52 Week Range||228.00 - 459.75|
|Beta (3Y Monthly)||1.03|
|PE Ratio (TTM)||47.05|
|Earnings Date||Aug 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||334.38|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Abiomed Inc NASDAQ/NGS:ABMDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ABMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ABMD are favorable, with net inflows of $8.11 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The Company will host a conference call to discuss the results on Thursday, August 1, 2019, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.
Today we'll evaluate Abiomed, Inc. (NASDAQ:ABMD) to determine whether it could have potential as an investment idea...
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Abiomed’s (ABMD) Impella platform is being featured today at a Washington, D.C., event showcasing innovations in medical technology that improve healthcare for women. Abiomed’s participation supports its Women’s Initiative for Heart Recovery, which provides education and raises awareness of women’s cardiovascular diseases and the opportunity for heart recovery. One young woman who benefited from heart recovery with Impella support is Iman Dorty, who is speaking at today’s event.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Uber shares are popping today on word analysts practically all love the stock. But turns out, it's not the only stock showered with "buy" ratings from analysts. The question, though, is whether that should matter to investors.
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abiomed, Inc. , a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer
Abiomed Inc (NASDAQ:ABMD) files its latest 10-K with SEC for the fiscal year ended on March 31, 2019.
Months after federal regulators warned doctors that one of the heart pumps made by Danvers’ Abiomed could be linked to a higher rate of death than previously thought, the company’s device has been cleared by the FDA.
The Standard & Poor's 500 index—commonly called the S&P 500, or simply the S&P—is the primary gauge of the large-cap U.S. equities market. It is based on the market capitalization figures of the top 500 companies that list their common stock on the NYSE or NASDAQ. Based on available historical data, the S&P has generated an average annual return of around 9.8% from 1928 through 2016.
Use of early identification protocol leads to higher survival and native heart recovery, as demonstrated in FDA studies